Company Overview

DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company operates within the biotechnology and pharmaceutical industries, with its core activity centered on immunotherapy platforms designed to desensitize patients to allergens rather than treat acute allergic reactions. DBV Technologies does not currently generate significant commercial revenue and is primarily funded through equity offerings and strategic financings.

The company’s primary product candidate and revenue driver in development is Viaskin Peanut, a non-invasive epicutaneous immunotherapy intended to treat peanut allergy, particularly in pediatric populations. DBV Technologies serves patients with severe food allergies, healthcare providers, and regulatory health systems, with a strategic focus on addressing unmet medical needs where no FDA-approved disease-modifying therapies are widely available. Founded in 2002, the company evolved from early-stage immunology research into a late-stage clinical development organization, with a strong emphasis on regulatory engagement in the United States and Europe.

Business Operations

DBV Technologies’ operations are organized around a single core platform, the Viaskin epicutaneous delivery system, which uses a proprietary patch to deliver allergens through intact skin to induce immune tolerance. The company’s lead program, Viaskin Peanut, has advanced through multiple late-stage clinical trials and represents the majority of its operational spending. Additional pipeline programs, including Viaskin Milk and Viaskin Egg, have been explored but remain secondary to the peanut allergy program.

Operationally, DBV Technologies conducts clinical development activities across North America and Europe, with clinical trials managed through third-party contract research organizations. The company does not own manufacturing facilities and relies on external partners for clinical supply manufacturing. DBV Technologies maintains wholly owned subsidiaries, including DBV Technologies Inc. in the United States, which supports regulatory, clinical, and corporate activities tied to the U.S. market.

Strategic Position & Investments

Strategically, DBV Technologies is focused on achieving regulatory approval for Viaskin Peanut, particularly with the U.S. Food and Drug Administration, following prior regulatory setbacks and subsequent clinical and manufacturing adjustments. Growth initiatives are centered on refining clinical protocols, addressing regulatory feedback, and securing additional capital to fund ongoing trials and operations. The company has emphasized disciplined capital allocation and prioritization of its lead asset over broader pipeline expansion.

DBV Technologies has not completed any transformative acquisitions and does not operate a diversified investment portfolio. Its strategic investments are primarily internal, directed toward clinical development, regulatory affairs, and intellectual property related to the Viaskin platform. The company remains selectively engaged in emerging immunotherapy technologies only insofar as they support or enhance its epicutaneous delivery approach. Data inconclusive based on available public sources regarding any material joint ventures beyond standard clinical and manufacturing partnerships.

Geographic Footprint

DBV Technologies is headquartered in Montrouge, France, and maintains a significant operational presence in the United States, which represents its most important regulatory and commercial target market. The U.S. operations are primarily conducted through DBV Technologies Inc., supporting clinical development, FDA interactions, and corporate functions.

The company’s clinical trial footprint spans Europe and North America, reflecting its focus on regions with established regulatory pathways for allergy immunotherapy and large addressable patient populations. While DBV Technologies does not have commercial operations in Asia-Pacific or other regions, its intellectual property and clinical data are intended to support potential future global commercialization, subject to regulatory approvals and strategic partnerships.

Leadership & Governance

DBV Technologies was founded by Pierre-Henri Benhamou, who played a key role in establishing the company’s scientific and entrepreneurial foundations. The current leadership team emphasizes regulatory rigor, clinical execution, and capital discipline as core elements of its strategic vision, with a stated focus on rebuilding credibility with regulators and investors following earlier clinical and regulatory challenges.

Key executives include:

• Christophe Rigaud – Chief Executive Officer
• Étienne Chabert – Chief Financial Officer

Publicly available sources confirm the roles listed above; information regarding additional executive appointments or recent leadership changes is data inconclusive based on available public sources. The company operates under a traditional governance structure with oversight from a board of directors, aligning management incentives with long-term shareholder value creation and regulatory success.